Xtant Medical Holdings, Inc. XTNT
We take great care to ensure that the data presented and summarized in this overview for Xtant Medical Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XTNT
View all-
Orbimed Advisors LLC San Diego, CA73.1MShares$34.4 Million1.17% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT11.4MShares$5.36 Million0.46% of portfolio
-
Altium Capital Management LP New York, NY7.42MShares$3.49 Million1.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$1.01 Million0.0% of portfolio
-
Juniper Investment Company, LLC New York, NY1.32MShares$619,9030.36% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny694KShares$326,2770.0% of portfolio
-
Geode Capital Management, LLC Boston, MA515KShares$242,0520.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA297KShares$139,6630.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX294KShares$137,9450.0% of portfolio
-
Crescent Grove Advisors, LLC212KShares$99,6510.02% of portfolio
Latest Institutional Activity in XTNT
Top Purchases
Top Sells
About XTNT
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Insider Transactions at XTNT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 15
2024
|
Sean E Browne President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
105,442
-4.59%
|
$0
$0.59 P/Share
|
Aug 15
2024
|
Stavros G. Vizirgianakis Director |
BUY
Grant, award, or other acquisition
|
Direct |
748,648
+5.2%
|
-
|
Aug 15
2024
|
Lori D Mitchell Keller Director |
BUY
Grant, award, or other acquisition
|
Direct |
162,162
+31.47%
|
-
|
Aug 15
2024
|
Robert Mc Namara Director |
BUY
Grant, award, or other acquisition
|
Direct |
162,162
+17.7%
|
-
|
Aug 15
2024
|
Jonn R. Beeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
162,162
+31.09%
|
-
|
Aug 15
2024
|
John K Bakewell Director |
BUY
Grant, award, or other acquisition
|
Direct |
162,162
+17.66%
|
-
|
Aug 15
2024
|
Kevin D Brandt Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
56,333
-5.63%
|
$0
$0.6 P/Share
|
Aug 15
2024
|
Scott C Neils Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,132
-5.14%
|
$0
$0.6 P/Share
|
Aug 15
2024
|
Sean E Browne President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,606
-0.46%
|
$0
$0.6 P/Share
|
Apr 03
2024
|
Kevin D Brandt Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
184,209
+15.55%
|
-
|
Apr 03
2024
|
Sean E Browne President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
731,632
+24.08%
|
-
|
Apr 03
2024
|
Mark A. Schallenberger Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
177,551
+31.69%
|
-
|
Apr 03
2024
|
Scott C Neils Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
177,551
+21.09%
|
-
|
Jan 16
2024
|
Scott C Neils Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,986
-1.61%
|
$7,986
$1.09 P/Share
|
Nov 17
2023
|
Kevin D Brandt Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
41,670
+4.86%
|
$41,670
$1.2 P/Share
|
Oct 15
2023
|
Sean E Browne President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
111,721
-6.65%
|
$111,721
$1.08 P/Share
|
Aug 15
2023
|
Mark A. Schallenberger Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
116,144
+36.15%
|
-
|
Aug 15
2023
|
Scott C Neils Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,246
-4.85%
|
$25,246
$1.18 P/Share
|
Aug 15
2023
|
Scott C Neils Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
116,144
+18.25%
|
-
|
Aug 15
2023
|
Sean E Browne President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
174,216
+9.39%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.67M shares |
---|---|
Open market or private purchase | 41.7K shares |
Payment of exercise price or tax liability | 214K shares |
---|